IRIS - Res&Arch Institutional Research Information System - Research & Archive

Roila, Fausto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.310
AS - Asia 1.991
EU - Europa 1.590
SA - Sud America 486
AF - Africa 45
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 2
AN - Antartide 1
Totale 6.427
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.229
SG - Singapore 1.088
IE - Irlanda 468
BR - Brasile 414
HK - Hong Kong 347
IT - Italia 317
CN - Cina 249
RU - Federazione Russa 227
VN - Vietnam 127
FR - Francia 117
DE - Germania 106
UA - Ucraina 71
SE - Svezia 63
FI - Finlandia 52
GB - Regno Unito 50
KR - Corea 37
CA - Canada 36
IN - India 28
MX - Messico 28
AR - Argentina 26
AT - Austria 24
ES - Italia 19
NL - Olanda 19
PL - Polonia 19
TR - Turchia 18
BE - Belgio 16
EC - Ecuador 16
ZA - Sudafrica 16
JP - Giappone 15
IQ - Iraq 14
BD - Bangladesh 13
ID - Indonesia 10
PY - Paraguay 9
CO - Colombia 8
PK - Pakistan 7
AE - Emirati Arabi Uniti 6
EG - Egitto 6
MA - Marocco 6
JM - Giamaica 5
SA - Arabia Saudita 5
CL - Cile 4
LT - Lituania 4
TT - Trinidad e Tobago 4
BG - Bulgaria 3
CH - Svizzera 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
HN - Honduras 3
JO - Giordania 3
KZ - Kazakistan 3
MY - Malesia 3
PE - Perù 3
PH - Filippine 3
TN - Tunisia 3
UY - Uruguay 3
UZ - Uzbekistan 3
AL - Albania 2
AZ - Azerbaigian 2
GE - Georgia 2
GH - Ghana 2
KE - Kenya 2
NP - Nepal 2
SN - Senegal 2
VE - Venezuela 2
AD - Andorra 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CZ - Repubblica Ceca 1
DJ - Gibuti 1
ET - Etiopia 1
EU - Europa 1
GR - Grecia 1
IS - Islanda 1
LY - Libia 1
MN - Mongolia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
PW - Palau 1
QA - Qatar 1
RO - Romania 1
SI - Slovenia 1
SO - Somalia 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
YT - Mayotte 1
Totale 6.427
Salva come PNG Salva come JPEG
Città #
Singapore 690
Dublin 468
Chandler 347
Hong Kong 346
Boardman 162
Santa Clara 151
Altamura 135
Ashburn 132
Princeton 130
Medford 127
Lawrence 124
Moscow 118
Los Angeles 77
Perugia 55
Ho Chi Minh City 53
São Paulo 50
New York 49
Beijing 37
Seoul 37
The Dalles 36
Jacksonville 35
San Mateo 33
Munich 29
Helsinki 26
Redmond 26
Andover 25
Ann Arbor 25
Nuremberg 21
Hanoi 20
San Paolo di Civitate 20
Dallas 18
Warsaw 18
Brussels 16
Piscataway 16
Rome 16
Wilmington 16
Shanghai 15
Brooklyn 14
Chicago 14
Houston 14
Frankfurt am Main 13
Montreal 13
Tokyo 13
Chennai 12
Rio de Janeiro 12
Columbus 11
Napoli 11
San Francisco 11
Amsterdam 10
Brasília 10
Denver 10
Falkenstein 10
Guayaquil 10
Stockholm 10
Toronto 10
Turku 10
Atlanta 9
Johannesburg 9
Ankara 8
Boston 8
Boydton 8
London 8
Mexico City 8
Bologna 7
Guangzhou 7
Huskvarna 7
Norwalk 7
Orem 7
Vienna 7
Baghdad 6
Belo Horizonte 6
Des Moines 6
Milan 6
Poplar 6
Porto Alegre 6
Tianjin 6
Woodbridge 6
Charlotte 5
Haiphong 5
Istanbul 5
Lappeenranta 5
Manchester 5
Phoenix 5
Recife 5
Seattle 5
São José dos Campos 5
Wuhan 5
Asunción 4
Bexley 4
Buenos Aires 4
Cairo 4
Campinas 4
Changsha 4
Cincinnati 4
Contagem 4
Curitiba 4
Erbil 4
Hefei 4
Kingston 4
Lahore 4
Totale 4.167
Salva come PNG Salva come JPEG
Nome #
Primitive thyroid lymphomas 120
Supportive care in cancer—a MASCC perspective 110
Efficacy of Pembrolizumab Monotherapy in Patients with or without Brain Metastases from Advanced Non-Small Cell Lung Cancer with a PD-L1 Expression ≥50% 103
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool 101
Invasive ductal carcinoma arising in ectopic breast tissue of the axilla. Case report and review of the literature 96
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy 95
High incidence of brain metastases in HER2-overexpressing metastatic breast cancer (MBC) patients (PTS) responsive to weekly paclitaxel (P) and trastuzumab (T) treatment. 5 National Congress of Medical Oncology, Rome, 21-24 October 2003. 90
Linee guida per la gestione dei pazienti affetti da melanoma cutaneo 89
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 85
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients 83
Surgical treatment of primitive thyroid lymphoma 82
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 >= 50% who progress on first-line immunotherapy: real-world data from a European cohort 80
Renal malignant solitary fibrous tumor with single lymph node involvement: report of unusual metastasis and review of the literature. 78
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab 75
2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy 72
Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines 72
Aprepitant Versus Dexamethasone for Preventing Chemotherapy-Induced Delayed Emesis in Patients With Breast Cancer: A Randomized Double-Blind Study 70
Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in Italy 70
NICSO: Network Italiano Cure di Supporto in Oncologia – Italian Network for Supportive Care in Oncology 69
XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. 68
Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment 68
Raccomandazioni cliniche per il melanoma cutaneo 67
Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations 67
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 66
Incidence, characteristics and treatment of fatigue in oncological cancer patients (PTS) in Italy: A cross-sectional study. 64
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial 64
Optimizing the risk stratification of astrocytic tumors by applying the cIMPACT-NOW Update 3 signature: real-word single center experience 62
Ginger in the management of chemotherapy induced nausea and vomiting (CINV), in patients receiving high dose cisplatin: a multicenter, randomized, double-blind, placebo-controlled study 62
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy 61
Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis 61
Aprepitant versus metoclopramide, both combined with dexamethasone, for preventing cisplatin-induced delayed emesis: A randomized, double-blind study 61
2016 updated MASCC/ESMO consensus recommendations: prevention of radiotherapy-induced nausea and vomiting 60
Italian nivolumab expanded access programme: real-world results in non-squamous non-small cell lung cancer patients 59
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients 59
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: An effective but still broken option 59
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: A randomized, double-blind study 58
Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis 58
Acute emesis: moderately emetogenic chemotherapy 58
Aprepitant (AP) versus dexamethasone (D) for preventing delayed emesis induced by anthracyclines plus cyclophosphamide (A plus C) chemotherapy (CT) in breast cancer patients (pts): A double-blind, multicenter, randomized study 58
Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer 57
Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009 57
Real-World Results in Non-Squamous Non-Small Cell Lung Cancer Patients: Italian Nivolumab Expanded Access Program 55
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr 55
Optimal Management of Fatigue 55
Prevalence and spectrum of brca germline variants in central Italian high risk or familial breast/ovarian cancer patients: A monocentric study 54
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference 54
Targeted therapy for advanced cutaneous melanoma 52
Juvenile papillomatosis of the breast in young male: a case report 52
A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin 51
Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time? 51
Prevention and treatment of pandemic influenza in cancer patients. 50
State of the art of antiemetic therapy 50
Efficacy of neurokinin-1 receptor antagonists in the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in patients receiving carboplatin-based chemotherapy: a systematic review and meta-analysis 50
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma 50
Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature 50
Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review 49
DOACs in patients with brain cancers: promising but still a long way to go 48
BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors 48
New antiemetic drugs 48
A new payment-by-results method for determining the fair price of new oncological drugs 47
Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy 47
Incidence, characteristics and treatment of fatigue in oncological cancer patients (pts) in italy: a cross-section study 47
Diagnosis and therapeutic management of parathyroid cancer, starting from the description of a clinical case 47
Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis 46
Aprepitant Versus Dexamethasone for Delayed Emesis: What Is the Role of the 5-Hydroxytryptamine Type 3 Receptor Antagonist Palonosetron? Reply 46
Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two cases 45
RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature 45
Hepatitis B in immunosuppressed cancer patients:pathogenesis, incidence and prophylaxis 45
A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients 45
Efficacy and safety data from patients with advanced non-squamous NSCLC and brain metastases from the nivolumab expanded access programme (EAP) in Italy 45
Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry Study 44
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference 44
Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer (Oncology and Therapy, (2024), 12, 1, (163-171), 10.1007/s40487-023-00251-6) 43
Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations 40
Developing clinical recommendations for breast, colorectal, and lung cancer adjuvant treatments using the GRADE system: A study from the programma Ricerca e Innovazione Emilia Romagna oncology research group 39
ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis 38
Chemotherapy-induced nausea and vomiting 38
Management of febrile neutropenia: ESMO Clinical Recommendations 38
Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis 38
Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations 37
The cost of chemotherapy-induced nausea and vomiting in Italy 37
Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines 36
Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol-EASE 36
The impact of chemotherapy-induced nausea and vomiting on health-related quality of life 36
Conflict of interest among Italian medical oncologists: A national survey 36
Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review 36
Immunotherapy in Underrepresented Populations of Patients with Cancer: Do We Have Enough Evidence at Present? A Focus on Patients with Major Viral Infections and Autoimmune Disorders 36
Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain 36
Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management 35
Evaluation of Risk Factors Predicting Chemotherapy-Related Nausea and Vomiting: Results From a European Prospective Observational Study 35
Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO) 35
Palonosetron (PALO) plus dexamethasone (DEX) administered on day only prevents emesis and avoids prolonged DEX use in breast cancer patients treated with anthracycline/cyclophosphamide regimens 35
Management of cancer pain: ESMO Clinical Practice Guidelines 35
Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy 34
Management of oral and gastrointestinal mucositis: ESMO Clinical Recommendations 34
Update on anticancer drugs 34
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines 34
Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines 34
Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use 33
Malignant glioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up 33
Totale 5.520
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.837
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.837
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202172 0 0 0 0 0 8 10 1 23 10 16 4
2021/2022522 3 29 6 11 7 2 4 160 8 24 21 247
2022/20231.478 150 371 32 57 105 78 0 53 557 9 45 21
2023/2024585 28 47 25 14 10 2 128 13 39 40 107 132
2024/20251.771 9 165 27 63 198 74 50 147 470 116 268 184
2025/20261.987 306 230 263 462 495 231 0 0 0 0 0 0
Totale 6.595